Volume 1,Issue 3
A Review of the Correlation between Disease Outcomes in Female Patients with Immune Thrombocytopenic Purpura and the Lung-Heat and Kidney-Deficiency Syndrome
Immune thrombocytopenic purpura (ITP) is an autoimmune hematological disorder characterized by excessive peripheral platelet destruction and impaired bone marrow megakaryocyte production. The disease outcomes vary significantly among different genders and age groups, with female patients often exhibiting a more complex disease progression due to factors such as unique endocrine changes, immune dysregulation, and traditional Chinese medicine (TCM) constitutional characteristics. Recent studies have suggested a potential significant association between the TCM Lung-Heat and Kidney-Deficiency syndrome and the progression and prognosis of ITP. However, the underlying mechanisms remain incompletely understood. This review summarizes the characteristics of disease outcomes in female patients with ITP, including clinical phenotypes, treatment responses, and long-term prognosis. It also delves into the pathological basis of the Lung-Heat and Kidney-Deficiency syndrome in TCM and its potential link to the disease outcomes of ITP. Additionally, this review evaluates the potential role of integrated traditional Chinese and Western medicine in improving disease outcomes for female patients with ITP and proposes directions for future research, aiming to provide evidence-based guidance for optimizing individualized treatment plans.
[1] Gutiérrez-Brito J, Lomelí-Nieto J, Muñoz-Valle J, et al., 2025, Sex Hormones and Allergies: Exploring the Gender Differences in Immune Responses. Front Allergy, 5:1483919.
[2] Kasai J, Aoki S, Kamiya N, et al., 2015, Clinical Features of Gestational Thrombocytopenia Difficult to Differentiate from Immune Thrombocytopenia Diagnosed During Pregnancy. J Obstet Gynaecol Res, 41(1):44–49.
[3] Chu T, Hu S, Qi J, et al., 2022, Bifunctional Effect of the Inflammatory Cytokine Tumor Necrosis Factor α on Megakaryopoiesis and Platelet Production. J Thromb Haemost, 20(12):2998–3010.
[4] Jin X, Zhang Y, Zhuang J, 2023, Progress in the Diagnosis and Treatment of Hematological Toxicity Associated with Immune Checkpoint Inhibitors. Journal of Clinical Internal Medicine, 40(2):73–78.
[5] Liu L, Wang Y, Dong X, et al., 2019, Case Report of Two Patients with LRBA Gene Mutations. Chinese Journal of Evidence-Based Pediatrics, 14(1):25–29.
[6] Zhang T, Chen Z, Hong L, et al., 2023, Case Analysis of One Patient with Persistent Grade 4 Thrombocytopenia Induced by Pembrolizumab. Journal of Oncology Pharmacy, 13(5):644–648.
[7] Xu T, Cui Y, Li Z, et al., 2024, Analysis of PD-1/PD-L1 Expression Characteristics in ITP Patients and Its Interaction Mechanism Between Treg and Breg Cells. Western Medicine, 36(4):608–613.
[8] Lopez-Herrera G, Tampella G, Pan-Hammarström Q, et al., 2020, LRBA Deficiency Causes Absence of CTLA-4 in Lymphocytes and Autoantibody Production in Patients with Immune Thrombocytopenia. Blood, 135(10):789–801.
[9] Ma J, Zhang R, Wu Y, et al., 2018, Gene Diagnosis of Immune Thrombocytopenia Onset in 22q11.2 Microdeletion Syndrome: A Case Report of Partial DiGeorge Syndrome and Literature Review. Thrombosis and Hemostasis, 24(3):409–413.
[10] Chu T, Hu S, Qi J, et al., 2022, Bifunctional Effect of the Inflammatory Cytokine Tumor Necrosis Factor α on Megakaryopoiesis and Platelet Production. J Thromb Haemost, 20(12):2998–3010.
[11] Psaila B, Bussel J, 2007, Immune Thrombocytopenic Purpura. Hematol Oncol Clin North Am, 21(4):743–759.
[12] Holásková I, Franko J, Goodman R, et al., 2015, The XX Sex Chromosome Complement Is Required in Male and Female Mice for Enhancement of Immunity Induced by Exposure to 3,4-Dichloropropionanilide. Am J Reprod Immunol, 74(2):136–147.
[13] Sakkas L, Chikanza I, 2024, Gender Bias in Immune Response: It Is Time to Incorporate the Gender Variable into Studies of Autoimmune Rheumatic Diseases. Rheumatol Int, 44(2):203–209.
[14] Kawaguchi K, Matsubara K, Takafuta T, et al., 2014, Predictive Factors for Neonatal Thrombocytopenia in Pregnant Women with Immune Thrombocytopenia. Int J Hematol, 99(5):570–576.
[15] Sun D, Shehata N, Ye X, et al., 2016, Comparison of Corticosteroids and Intravenous Immunoglobulin for the Treatment of Immune Thrombocytopenia During Pregnancy. Blood, 128(10):1329–1335.
[16] Gao L, 2022, Retrospective Analysis of Clinical Efficacy and Study on the Pattern of Prescription and Medication in the Treatment of Refractory Thrombocytopenic Purpura by Zeng Yingjian, thesis, Jiangxi University of Traditional Chinese Medicine.
[17] Huang Q, Zhu X, Qu Q, et al., 2021, Predicting Postpartum Hemorrhage in Pregnant Women with Immune Thrombocytopenia: Development and Validation of the MONITOR Model in a Nationwide Multicenter Study. American Journal of Hematology, 96(5):561–570.
[18] Zhang Y, Feng S, Yang X, 2000, Clinical Study on Immune Disorder in Kidney Deficiency Syndrome of Chronic Idiopathic Thrombocytopenic Purpura. Journal of Xi’an Medical University (Chinese Version), 2000(2):119–120 + 149.
[19] Schifferli A, Moulis G, Godeau B, et al., 2023, Adolescents and Young Adults with Newly Diagnosed Primary Immune Thrombocytopenia. Haematologica, 108(10):2783–2793.
[20] Abadi U, Yarchovsky-Dolberg O, Ellis M, 2015, Immune Thrombocytopenia: Recent Advances in Pathophysiology and Treatment. Clinical and Applied Thrombosis/Hemostasis, 21(5):397–404.
[21] Sankaran S, Robinson S, 2011, Immune Thrombocytopenia and Pregnancy. Obstet Med, 4(4):140–146.
[22] van Dijk W, Punt M, van Galen K, et al., 2022, Menstrual Problems in Chronic Immune Thrombocytopenia: A Monthly Challenge–A Cohort Study and Review. Br J Haematol, 198(4):753–764.
[23] Li R, Li M, Ni R, et al., 2023, Systematic Evaluation and Meta-Analysis of Integrated Traditional Chinese and Western Medicine in the Treatment of Primary Immune Thrombocytopenia. Journal of Tianjin University of Traditional Chinese Medicine, 42(6):714–724.
[24] Tian X, Zhang H, Shen Y, et al., 2023, Pathogenesis, Diagnosis, and Treatment of Thrombocytopenia During Pregnancy and Its Impact on Pregnancy Outcomes. Chinese Journal of Clinical Obstetrics and Gynecology, 24(3):329–331.
[25] Bu S, Liu M, Yang L, et al., 2025, The Function of T Cells in Immune Thrombocytopenia. Front Immunol, 16:1499014.
[26] Jin Z, He Z, Xu T, 2021, Research Progress on Immune-Related Adverse Events of Immunosuppressants in Tumor Immunotherapy. China Pharmaceuticals, 30(20):1–5.
[27] Azizi G, Hesari M, Sharifinejad N, et al., 2023, Autoimmune Manifestations in Patients with Genetic Defects in B Cell Development and Differentiation Stages. Journal of Clinical Immunology, 43(4):819–834.
[28] Soodeh G, Mahnaz J, Hassan A, et al., 2023, Demographic, Clinical, Immunological, and Molecular Features of the Iranian National Cohort of Patients with Defects in the DCLRE1C Gene. Allergy, Asthma and Clinical Immunology, 19(1):13–13.